George Mashini Joins Welsh, Carson, Anderson & Stowe as An Operating Partner in the Firm s Technology Group
News provided by
Share this article
Share this article
NEW YORK, Jan. 15, 2021 /PRNewswire/ Welsh, Carson, Anderson & Stowe (WCAS), a leading private equity firm focused exclusively on the technology and healthcare industries, announced today that George Mashini has joined the firm as an Operating Partner.
Mr. Mashini has over 15 years of technology leadership experience. Most recently, he was Chief Revenue Officer and Chief Technology Officer at Quick Base, a WCAS portfolio company offering a leading low-code development platform. As Chief Revenue Officer at Quick Base, he led a complete transformation of the company s go to market program including rebuilding the sales team, which resulted in a significant increase in bookings and more than doubling in the number of enterprise accounts. While serving as Chief Technology Officer, he revamped Quick Base s cloud platform,
Share this article
Share this article
ResearchAndMarkets.com s offering.
According to the findings of a study by the University of California, Irwin Medical Center, hip and knee replacement surgeries are on the rise owing to incrementing percentage of geriatrics and the mounting obesity rates in the US. Furthermore, the institute estimates that by 2030, the total number of knee replacements performed in the US will escalate by a whopping 600% as compared to that in 2005.
Subsequently, there will be an upsurge in demand for the instruments needed for those surgeries, which will significantly stroke the prospects in the global surgical instruments market, which had a value of $10.2 billion to $11.5 in 2019. Furthermore, opportunities in the surgical instruments market will be mounting at healthy CAGR of 6% to 6.5% during the forecast period of 2020 to 2025.
CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors Study highlights wide range of pediatric cancers in which NTRK fusions are more likely to occur, which could help prioritize testing for targeted treatment with FDA-approved TRK inhibitors
News provided by
Share this article
Share this article
PHILADELPHIA, Jan. 15, 2021 /PRNewswire/ In a large study of pediatric cancer patients, researchers from Children s Hospital of Philadelphia (CHOP) have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors. The researchers found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibit
NotiSphere Joins Strategic Marketplace Initiative (SMI)
NotiSphere, an innovative startup revolutionizing the way medical device recalls are communicated in the healthcare industry, today announced that it has joined SMI®, a non-profit, member-driven consortium of healthcare supply chain thought leaders
News provided by
Share this article
Share this article
LOS ANGELES, Jan. 15, 2021 /PRNewswire/ NotiSphere, a healthcare technology company focused on innovating the medical device recall alert process, today announced that it has joined SMI®, a non-profit, member-driven consortium of healthcare supply chain thought leaders.
Membership in this organization will enable NotiSphere to actively participate with other thought leaders to drive change within the industry, specifically the supply chain processes. NotiSphere is committed to improving the quality of healthcare delivery by increasing patient safety, lowering the cost of healthcare, and applying traceability principles t
The rising incidence of infectious diseases, increasing pandemics frequency, increasing R&D in the pharmaceutical and biotechnology industries for complex diseases, growth in stem cell research, and the rising prevalence of cancer are the major factors driving the growth of single-cell analysis market. However, the high cost of single-cell analysis products is a major factor hampering the growth of the Asia Pacific single-cell analysis market. Emerging economies such as Japan and China are providing lucrative opportunities for the players operating in the market.
The consumables segment accounted for the largest share of the market, by product segment, in 2019
Based on product, the APAC single-cell analysis market is segmented into consumables and instruments. The consumables segment accounted for the largest shareof the market in 2019. The frequent purchase of these products as compared to instruments, which are considered as a one-time investment, and their wide applications in r